ARTICLE | Company News
Astute sales and marketing update
October 22, 2012 7:00 AM UTC
Astute launched its NephroCheck test in Europe to determine the risk of acute kidney injury (AKI) in critically ill patients. The test is an immunoassay of two undisclosed biomarkers. The company did...